IFNG and neoplasm: The nanovesicles can be further loaded with the JAK inhibitor ruxolitinib to abolish chemoradiotherapy‐induced programmed death ligand 1 (PD‐L1) upregulation on the surface of the tumor cells, thereby prompting chemoradiotherapy‐induced immunotherapy by blocking the interferon gamma‐Janus kinase‐signal transducer and activator of transcription axis.